Inès Chevolet

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Max Schreuer, Yanina Jansen, Simon Planken et al. · The Lancet Oncology · 2017 · 184 citations

Medicine, Oncology, Pharmacology +16

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen et al. · Journal of Translational Medicine · 2016 · 138 citations · Full text

Medicine, Molecular Biology, Oncology +17

Characterization of the<i>in vivo</i>immune network of IDO, tryptophan metabolism, PD-L1, and<i>CTLA-4</i>in circulating immune cells in melanoma

Inès Chevolet, Reinhart Speeckaert, Max Schreuer et al. · OncoImmunology · 2015 · 109 citations · Full text

Medicine, Immunology, Oncology +17

Clinical significance of Koebner phenomenon in vitiligo

Nanja van Geel, Reinhart Speeckaert, J. De Wolf et al. · British Journal of Dermatology · 2012 · 90 citations

Dentistry, Oral Pathology, Dermatopathology +12

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells

Peter Dynoodt, Reinhart Speeckaert, Olivier De Wever et al. · International Journal of Oncology · 2013 · 80 citations · Full text

Life Sciences, Molecular Biology, Oncology +16